A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF).
about
State of the art management of metastatic gastroesophageal cancerA phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancerIdentification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decadesInfusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: a low cost effective regimenHigh curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of DigestiveBimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma.A pilot study of mitomycin, cisplatin and continuous infusion 5-fluorouracil (MCF) in advanced non-small-cell lung cancerAdjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study.FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) studyIntensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).Combination chemotherapy with 5-fluorouracil and heptaplatin as first-line treatment in patients with advanced gastric cancer.Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysisThe ERK MAP kinase-PEA3/ETV4-MMP-1 axis is operative in oesophageal adenocarcinoma.PEA3/ETV4-related transcription factors coupled with active ERK signalling are associated with poor prognosis in gastric adenocarcinoma.Controversies and challenging therapeutic modalities in gastric cancer.Advanced gastric cancer in jordan from 2004 to 2008: a study of epidemiology and outcomesFOXM1 and polo-like kinase 1 are co-ordinately overexpressed in patients with gastric adenocarcinomas.Palliative chemotherapy for advanced gastric cancer.A pilot study evaluating the safety and toxicity of epirubicin, cisplatin, and UFT (ECU regimen) in advanced gastric carcinomaPhase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimenA phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancerEpirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancerWeekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin: an effective chemotherapy in advanced gastric cancer.Chemotherapy for gastric cancer.A case of virilization induced by a Krukenberg tumor from gastric cancerReport of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF.A dose-finding study of raltitrexed (tomudex) with cisplatin and epirubicin in advanced gastro-oesophageal adenocarcinoma.Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer.Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer.Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumoursAdjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation.Chemotherapy in metastatic gastric cancer: population-based perceptions and practice patterns of medical oncologists.Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers.Chemotherapy for advanced gastric cancer: slow but further progress.Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).Patient-reported outcomes evaluating palliative radiotherapy and chemotherapy in patients with oesophageal cancer: a systematic review.Combination chemotherapy in advanced gastrointestinal cancers: ex vivo sensitivity to gemcitabine and mitomycin C.The effect of the gastrectomy on survival in patients with metastatic gastric cancer: a study of ASMO.Preliminary trial of surgery after chemotherapy for advanced gastric cancer with peritoneal dissemination.
P2860
Q26779217-B963C31F-4D5E-4876-8436-F46C08457F20Q28350903-98589E48-0C99-405B-897D-D8CC9306EB3EQ30300756-404C2D79-C85F-42AF-B18A-107090682901Q33341264-75A1ECC7-713B-435D-9551-FCF20A6C0A48Q33360403-208EA5FE-0B1C-43AB-A1A4-4CBE29F50586Q33403949-4CB21AFB-595D-4D07-A7CE-FBF32500B777Q33489857-26792D24-6616-4FF2-B97B-414DA5A59394Q33490610-9A3A8E98-0122-4ABB-BD8A-3CECB06D5004Q33502314-AE918A05-D22E-4F2C-B674-6B9C9A1338C9Q33503301-A1657314-47FE-47D7-AFAE-2203387A68DAQ33631546-69417EFF-66F2-42B5-9B25-5E4E35023A0DQ33912151-6166F4F9-F831-4C8D-8FBA-C00210CDD01AQ34437805-48B36FC4-844E-4AFB-92A0-EDBC3F539035Q35108347-47E80248-FAB7-4B3E-8EC1-BA49DE6BE156Q35129981-CAE28E2F-74E8-4255-BDD6-3E5E9979D4C5Q35768031-FF59416D-79FD-41E3-83B6-F236BD4818A8Q35843942-C43055D9-15C5-41F5-92AC-4CB73938CC0EQ35936039-AC531993-7DAD-4802-B403-3E094DC80472Q36097126-57E4DB06-F9C5-4D00-B0D5-A06D6F09D5E6Q36134929-AAEEDC09-5D37-427F-8396-C6397725EC37Q36135201-DFBABC48-6950-4D39-8A5D-74005BC56FC6Q36136558-7767C1F8-F0D4-4F4D-B1E4-9C6D3D739253Q36292847-A8D58E01-6DA4-4D70-ACE1-2B8853A6DB90Q36398226-DDEE11C0-4289-41F5-B5B5-7C7308766610Q36510608-61584C0A-544C-4524-B2E1-86FD0AC7FFD3Q36615965-AE2AA72A-979C-4C06-B827-5F38E6261EE8Q36620979-AA1A764B-5611-4129-93D4-5318FC3A85C0Q36625990-4529CAC7-08C6-49C6-87E8-86D422F84FFFQ36644681-96209498-5671-4AB7-A5FF-5B0FC7FB1205Q36648316-3C9FFFA5-5583-457B-84C5-F7D86E587125Q36671309-01ACD533-EF9E-4C23-A0F4-59C066888B3FQ36694149-4FE96424-5F17-41C5-BB6D-DE2D0C710DF9Q37077239-77197A56-E0C6-4FD6-9764-38EA3D599008Q37446941-E6ABB8DB-FDA9-4754-A706-630D46BF0760Q37467770-7E852BA0-FE14-44ED-8BA1-06BF0C007070Q37689109-A7D55576-9FF8-4DE0-9F1C-638F87F5C2F2Q38063344-C0E54322-6B8D-4600-93DB-6DF2EA5466ADQ38611177-857DF85D-17F1-45A8-A545-136BD095A097Q38919830-29B9F0CD-D22B-48F7-89DD-1E6DB187C0EAQ41889228-C9BB6283-F6E6-48B2-B498-FC0B1C073432
P2860
A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF).
description
1994 nî lūn-bûn
@nan
1994 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
A phase II study in advanced g ...... infusion 5-fluorouracil (ECF).
@ast
A phase II study in advanced g ...... infusion 5-fluorouracil (ECF).
@en
type
label
A phase II study in advanced g ...... infusion 5-fluorouracil (ECF).
@ast
A phase II study in advanced g ...... infusion 5-fluorouracil (ECF).
@en
prefLabel
A phase II study in advanced g ...... infusion 5-fluorouracil (ECF).
@ast
A phase II study in advanced g ...... infusion 5-fluorouracil (ECF).
@en
P2093
P1433
P1476
A phase II study in advanced g ...... infusion 5-fluorouracil (ECF).
@en
P2093
M Nicolson
V Nicolson
P304
P356
10.1093/OXFORDJOURNALS.ANNONC.A058932
P577
1994-09-01T00:00:00Z